Twitter

$AMBS opened IND application to advance #eltoprazine into Ph 2b trial: [link]

#levodopa-induces #dyskinesia
Ph 2a study results published in @Brain1878 for the treatment of #Parkinson #levodopaindices #dyskinesia [link] $AMBS
$AMBS receives notice of allowance from U.S patent app for proprietary methods of
admin of #eltoprazine: [link]
Corp & clinical devl achiev for the Therapeutics division & subsidiary Amarantus
Diagnostics Inc. in 1Q [link] $AMBS
Click to learn about $AMBS Q1 financial results and business overview [link]
#eltoprazine #dyskinesia
$AMBS management to host conference call and webcast on Wednesday May 27 at
5pm EDT:[link]
Facebook/Google+/Linkedin
Amarantus expects eltoprazine phase 2b clinical program to commence in the second
quarter of 2015.One of our key priorities has been to prepare for the initiation of the
Phase 2b clinical study of our lead therapeutic product candidate, eltoprazine, in
Parkinsons disease levodopa-induced dyskinesia, said CEO Gerald Commissiong, We
have made tremendous progress moving this forwards and are on track to commence
the study this quarter. [link]